AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04736433
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor dispensing claim is used as the reference
Trial: NCT02953535
Drug: Magicbuvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 400 mg sofosbuvir
Trial: NCT00493870
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
Trial: NCT00493870
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV over 15-30 minutes on Day 1.
Trial: NCT03004118
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 week oral intake (daily)
Trial: NCT03004118
Drug: Ursochol oral tablet
RxNorm normalized name: ursodiol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 week oral intake (daily) (dose of 10.5mg/kg/day)
Trial: NCT05655338
Drug: systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03697187
Drug: rhC1INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human C1 inhibitor
Trial: NCT02695472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered
Trial: NCT00763139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By mouth once a day for 8 weeks
Trial: NCT01256437
Drug: Threolone ointment
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ointment once daily for 1 month
Trial: NCT01256437
Drug: ointment Synthomycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ointment once daily for 1 month
Trial: NCT02055716
Drug: Sulforadex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
Trial: NCT00542555
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01330238
Drug: Zoledronic acid vs. placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single infusion of zoledronic acid or placebo
Trial: NCT00948870
Drug: Shugan decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoction ,two times a day,one bag of decoction one time
Trial: NCT00933049
Drug: Cotrimoxazole placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01068132
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
Trial: NCT00003746
Drug: 2-chlorodeoxyadenosine (CDA) daily
RxNorm normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily administration
Trial: NCT00003746
Drug: 2-chlorodeoxyadenosine weekly
RxNorm normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration
Trial: NCT02698735
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
Trial: NCT02698735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
Trial: NCT00670592
Drug: HCD122
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00907400
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT02449655
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
Trial: NCT00958204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Pill: one oral tablet each day, for 8 weeks.
Trial: NCT00958204
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine: 20 mg oral tablet each day, for 8 weeks
Trial: NCT02268058
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine administration of medication for a 72 hour period
Trial: NCT02268058
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: routine administration of medication for a 72 hour period
Trial: NCT02449655
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
Trial: NCT02076698
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual treatment of epilepsy Vagus nerve stimulation: maintained
Trial: NCT02906618
Drug: LY3039478
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02364479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The injection method and frequency of placebo is the same as the other arms.
Trial: NCT01926782
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Trial: NCT01926782
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
Trial: NCT03516760
Drug: GEM333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of GEM333; administered intravenously and continuously over 10 days
Trial: NCT04344678
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esitalopram 20 mg tablet plus placebo tablet once daily
Trial: NCT02870855
Drug: intrauterine injection of HCG
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrauterine injection of HCG berore blastocyst transfer
Trial: NCT01936532
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months.
Trial: NCT02560610
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02560610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01246791
Drug: NPC-01
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
Trial: NCT00739414
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
Trial: NCT04077905
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35mg/m² ivgtt on day 1
Trial: NCT00689572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
Trial: NCT01523990
Drug: TG-2349
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
Trial: NCT04031703
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide chemotherapy (injection)
Trial: NCT03828929
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
Trial: NCT01286246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
Trial: NCT01523990
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
Trial: NCT01871532
Drug: Gonal-f®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00149578
Drug: Gemcitabine Oxaliplatin 5FU and Leucovorin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03115151
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
Trial: NCT03403205
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1840 administered orally in 15 mg tablets
Trial: NCT01622881
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
Trial: NCT03379389
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics based on individual subjects urine culture / antibiogram
Trial: NCT00725075
Drug: MK-8435 (Org 25935) 4-8 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
Trial: NCT01728064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00725075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for MK-8435 (Org 25935) administered orally BID
Trial: NCT00725075
Drug: MK-8435 (Org 25935) 12-16 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally BID for a final concentration of 24-32 mg/day
Trial: NCT03823612
Drug: GC tooth mousse
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
Trial: NCT02727283
Drug: GSK3179106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
Trial: NCT02727283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
Trial: NCT02326779
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
Trial: NCT02100917
Drug: DMB-3111
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02579733
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02579733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01405248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/time per os three times a day. 180days
Trial: NCT03174522
Drug: REX-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REX-001 is administered through an intra-arterial catheter.
Trial: NCT03174522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered through an intra-arterial catheter.
Trial: NCT01818232
Drug: [14C]-LX4211
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00352105
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg.m2/d IV continuous x 4 days
Trial: NCT01505907
Drug: CXB909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXB909
Trial: NCT02889432
Drug: Oral Melatonin 10mg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02889432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03667703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to either receive a placebo or famotidine (study drug).
Trial: NCT00311467
Drug: Capecitabine, Interferon, Interleukin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups
Trial: NCT06517134
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of antihypertensive drugs
Trial: NCT01843855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A saline infusion will be given to match the study drug infusion.
Trial: NCT00866307
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00866307
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00866307
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00866307
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT and PO
Trial: NCT01585792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01804244
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 25-mg tablet \[27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
Trial: NCT00538031
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00671255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
Trial: NCT00538031
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01902550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
Trial: NCT01167829
Drug: Oral Testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
Trial: NCT00713583
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 800mg levodopa and 200mg carbidopa per day
Trial: NCT00767897
Drug: Human Papillomavirus Vaccine
RxNorm normalized name: human papillomavirus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
Trial: NCT00802685
Drug: Early ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen.
Trial: NCT04506372
Drug: Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
Trial: NCT03800875
Drug: 27-hour inpatient intervention
RxNorm normalized name: Impatiens Balsamina Leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
Trial: NCT02271412
Drug: LY03005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
Trial: NCT02271412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01545700
Drug: Control-saline
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomized to receive saline 2 cc
Trial: NCT01545700
Drug: Control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomized to receive saline 2 cc
Trial: NCT03861143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily tablet
Trial: NCT00281879
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
Trial: NCT00281879
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered on days +1, +3, and +7.
Trial: NCT05043467
Drug: Duvie(Lobeglitazone) tab 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
Trial: NCT01777581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no